Severe psoriasis treated with a new macrolide: everolimus
Severe psoriasis treated with a new macrolide: everolimus
复制标题
DOI：
10.1111/j.1365-2133.2006.07602.x
复制
发表时间：
2007-02-01
影响因子：
10.3
通讯作者：
Altomare, G. F.
中科院分区：
文献类型：
--
作者：
Frigerio, E.;Colombo, M. D.;Altomare, G. F.
银屑病是一种免疫介导的疾病，具有慢性复发过程，并且传统疗法难以治疗的特别严重的形式通常难以管理。依维莫司（Certican（（R））; Novartis，巴塞尔，瑞士）是一种新的雷帕霉素衍生的大环内酯，用于预防心脏和肾脏移植患者的排斥反应。其免疫抑制和抗增殖活性的机制与钙调磷酸酶抑制剂如环孢素不同，但互补。我们描述了一个严重银屑病的妇女用依维莫司联合亚治疗剂量的环孢素治疗。
Psoriasis is an immune-mediated disease with a chronic relapsing course, and the particularly severe forms that are refractory to traditional therapies are often difficult to manage. Everolimus (Certican((R)); Novartis, Basel, Switzerland) is a new rapamycin-derived macrolide that is used in the prophylaxis of rejection in heart and kidney transplant patients. The mechanism underlying its immunosuppressant and antiproliferative activity is different from, but complementary to, that of calcineurin inhibitors such as ciclosporin. We describe a woman with severe psoriasis treated with everolimus combined with subtherapeutic doses of ciclosporin.